hotspot -WSS

hotspot

author：hotspot 2025-10-02 13:37:39 - browse：58

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on Monday:

Should the patients who receive the medicine be limited based on PET scans of a protein called tau that Eli Lilly used as a key criteria for trying to determine whether they should receive the drug? That could reduce usage of the medicine by adding a barrier to its use.

And how do the potential risks of using the drug compare to its benefits? The FDA points to one analysis, admittedly with missing data, that could indicate patients who receive the drug have a higher risk of dying.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Why Congress must ban federal programs from using QALYs

WSS

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Mass General totes up its waste in a move to tackle climate change

BridgeBio heart drug succeeds in pivotal study

FDA seeking to stop procedures at two unregulated stem cell clinics

Why Congress must ban federal programs from using QALYs

knowledge

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Stanford president's case begs question: Who takes blame?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

US soldier in North Korean custody after crossing DMZ line

Sports medicine is finally prioritizing gender equality

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

Activists slam private health insurers over coverage restrictions

Study identifies new proteins linked to dementia risk 25 years later

Medicare details structure of new drug price negotiation program

Stanford president faces new allegations over 1999 paper

leisure time

Biden administration sends mixed signals on US soldier who crossed into North Korea

Biden administration sends mixed signals on US soldier who crossed into North Korea

US soldier in North Korean custody after crossing DMZ line

Divers poised to search for children washed away in Pennsylvania flash flood

Driven by the pandemic, applicants flood public health schools

House passes resolution saying Israel isn't a 'racist or apartheid state'

explore

focus

hotspot

hotspot